(CercleFinance.com) – New data from the Phase III HAVEN 6 study reinforce the favorable safety and efficacy profile of Roche’s Hemlibra in people with moderate or mild hemophilia A.
Hemlibra continues to demonstrate clinically meaningful bleed control, with 66.7% of participants with moderate or mild hemophilia A experiencing no treated bleeds after 55.6 weeks of median follow-up.
The new data also reinforce Hemlibra’s favorable safety profile, with no new safety signals observed.
Hemlibra is approved to treat people of all ages with hemophilia A with factor VIII inhibitors in more than 110 countries and for people of all ages without factor VIII inhibitors in more than 95 countries.
The data will be presented at the 30th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH), on July 11, 2022, in London and should form the basis of a Hemlibra update application to the European Agency drugs to include patients with non-severe haemophilia A.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
–
